{"id":32,"date":"2025-07-30T11:02:07","date_gmt":"2025-07-30T11:02:07","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=32"},"modified":"2025-07-30T13:29:03","modified_gmt":"2025-07-30T13:29:03","slug":"china-bd-deal-cspc-and-madrigal","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/32.html","title":{"rendered":"[China BD Deal] CSPC and Madrigal achieved a 2 billion license on GLP-1 R SYH2086"},"content":{"rendered":"\n<p><\/p>\n\n\n\n<p>Announced Date: 2025-07-30 (JULY 30, 2025)<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>Asset Name: SYH2086<\/p>\n\n\n\n<p>Licensor: CSPC Pharmaceutical Group Limited (HKEX Stock CodeL 1093) (CSPC)&nbsp;(Headquarter Shijiazhuang City, Hebei Province, China)<\/p>\n\n\n\n<p>Licensee (Buyer): Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL) (Madrigal) (Headquarter, West Conshohocken, PA 19428, USA)<\/p>\n\n\n\n<p>&nbsp;<\/p>\n\n\n\n<p>Asset Target:  Oral glucagon-like peptide-1 (GLP-1) receptor agonist<\/p>\n\n\n\n<p>Asset Modality: Small Molecule <\/p>\n\n\n\n<p>Current Stage: preclinical&nbsp;;  <\/p>\n\n\n\n<p>Madrigal plans to initiate clinical development in the first half of 2026.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>Scope of Authority: <\/p>\n\n\n\n<p>CSPC has granted Madrigal an exclusive global license to develop, manufacture, and commercialize SYH2086.&nbsp; <\/p>\n\n\n\n<p>CSPC may develop and commercialize other oral GLP-1 agonists in&nbsp;China subject to certain conditions. <\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>Deal Detail: <\/p>\n\n\n\n<p>Upfront payment of&nbsp;$120 million<\/p>\n\n\n\n<p>Milestone payments up to &nbsp;$2 billion (1.955 billion) (if certain development, regulatory and commercial milestones are achieved) <\/p>\n\n\n\n<p>Royalties on net sales, two digital<\/p>\n\n\n\n<p>Total 2.075 billion plus<\/p>\n\n\n\n<p>The transaction is anticipated to close in the fourth quarter of 2025, subject to the applicable regulatory clearance.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>Link:  <\/p>\n\n\n\n<p>Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited<\/p>\n\n\n\n<p><a href=\"https:\/\/ir.madrigalpharma.com\/news-releases\/news-release-details\/madrigal-pharmaceuticals-enters-exclusive-global-license\">https:\/\/ir.madrigalpharma.com\/news-releases\/news-release-details\/madrigal-pharmaceuticals-enters-exclusive-global-license<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-07-30 (JULY 30, 2025) Asset Name: SYH2086 Licensor: CSPC Pharmaceutical Group Limited (HKEX Stock &hellip; <a title=\"[China BD Deal] CSPC and Madrigal achieved a 2 billion license on GLP-1 R SYH2086\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/32.html\"><span class=\"screen-reader-text\">[China BD Deal] CSPC and Madrigal achieved a 2 billion license on GLP-1 R SYH2086<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-32","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/32","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=32"}],"version-history":[{"count":6,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/32\/revisions"}],"predecessor-version":[{"id":42,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/32\/revisions\/42"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=32"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=32"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=32"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}